Compare NX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | BBNX |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | 7071 | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.7M | 997.9M |
| IPO Year | 2008 | 2025 |
| Metric | NX | BBNX |
|---|---|---|
| Price | $19.20 | $18.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $26.00 | $23.28 |
| AVG Volume (30 Days) | 459.8K | ★ 1.3M |
| Earning Date | 09-03-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $1,837,641,000.00 | $100,251,000.00 |
| Revenue This Year | $1.98 | $25.74 |
| Revenue Next Year | $0.51 | $44.51 |
| P/E Ratio | $33.51 | ★ N/A |
| Revenue Growth | 43.81 | ★ 53.94 |
| 52 Week Low | $11.04 | $8.80 |
| 52 Week High | $23.33 | $32.71 |
| Indicator | NX | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 45.45 |
| Support Level | $18.30 | $15.76 |
| Resistance Level | $19.62 | $20.48 |
| Average True Range (ATR) | 0.73 | 1.65 |
| MACD | -0.23 | -0.33 |
| Stochastic Oscillator | 6.31 | 42.11 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.